ALEXION - Great Expectations From Label Expansion

September 2011 | 4 pages | ID: AA6B22AB154EN
MP Advisors

Abstracts

We have a positive expectation for the approval of Eculizumab (L, Soliris, Paroxysmal Nocturnal Hemoglobinuria) in Atypical Hemolytic Uremic Syndrome (aHUS, PDUFA on October 7th). Recent data presented in Myasthenia Gravis (MG) shows potential of eculizumab in other indications targeting rare and high unmet need along with robust growth opportunity in approved indication… For more details, please read our report released on September 16, 2011 on Alexion (ALXN), titled “Great Expectations From Label Expansion”.

Contents

COMPANIES MENTIONED

ALEXION